Quick Answer
Context Therapeutics Inc. reported Operating Income of -$39.70 million for fiscal year 2025.
Context Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$39.70M | -32.7% |
| 2024 | -$29.92M | -19.3% |
| 2023 | -$25.07M | -63.0% |
| 2022 | -$15.38M | -46.1% |
| 2021 | -$10.53M | -309.2% |
| 2020 | -$2.57M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$10.61M | +43.3% | -8.7% |
| June 30, 2025 | -$9.76M | -216.0% | -76.5% |
| March 31, 2025 | -$5.53M | -44.6% | +70.4% |
| September 30, 2024 | -$18.70M | -202.6% | -505.5% |
| June 30, 2024 | -$3.09M | +41.6% | +19.2% |
| March 31, 2024 | -$3.82M | +42.6% | +38.1% |
| September 30, 2023 | -$6.18M | -52.7% | -16.8% |
| June 30, 2023 | -$5.29M | -32.1% | +20.6% |
- Context Therapeutics Inc. showed a decrease of -32.7% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Context Therapeutics Inc.’s operating income has declined by 1443.5% (from -$2.57 million to -$39.70 million).
- The most recent figure is from Context Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: